Loading...
CLLS logo

Cellectis S.A.NasdaqGM:CLLS Stock Report

Market Cap US$232.2m
Share Price
US$3.09
US$7.27
57.5% undervalued intrinsic discount
1Y132.3%
7D1.0%
1D
Portfolio Value
​
View

Cellectis S.A.

NasdaqGM:CLLS Stock Report

Market Cap: US$232.2m

Cellectis (CLLS) Stock Overview

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. More details

CLLS fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 92.5% below our estimate of its fair value

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 16.1% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years


CLLS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Cellectis S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cellectis
Historical stock prices
Current Share Price€3.09
52 Week High€5.48
52 Week Low€1.33
Beta2.75
1 Month Change-22.36%
3 Month Change-9.65%
1 Year Change132.33%
3 Year Change47.14%
5 Year Change-79.19%
Change since IPO-91.73%

Recent News & Updates

Recent updates

Seeking Alpha • Dec 18

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This

Summary Cellectis is downgraded to Hold after a 150% rally, as valuation now outpaces near-term catalysts. Lasme-cel's phase 2 data in R/R-ALL show promising CR/CRi rates, but pivotal readout timelines remain unclear. CLLS's cash runway extends into H2 2027, yet likely insufficient for full approval and commercialization without additional funding. Cell therapy sector headwinds and unresolved UCART19 licensing disputes add risk, suggesting patience for a better entry point. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Cellectis: Poised To Start Answering Questions In 2025

Summary Cellectis S.A.'s pipeline updates highlight promising advancements in engineered, allogeneic cell therapies. The financial overview indicates a strong cash position, but ongoing R&D expenses pose a risk to its longevity. Key data updates are coming in 2025 that will give us a look at their lead program in a larger population. Bottom-line: Based on these catalysts and relative financial stability, I am revising my sentiment upward for now, but this still has a lot of risk. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Cellectis: Cheap With Promising But Speculative Cancer Therapies

Summary Cellectis S.A. leverages its UCART platform and TALEN gene-editing technology to develop innovative, off-the-shelf CAR-T therapies for cancer treatment. UCART22, a key candidate in Cellectis’s pipeline, shows promising efficacy and safety for ALL with CLLS52. The company's promising pipeline also includes UCART20x22 for NHL with a favorable safety profile. However, Cellectis' IP remains in Phase 1 or earlier stages, making it a long-term speculative commitment for investors. Despite its speculative nature, Cellectis S.A.'s cheap valuation and sufficient resources make it a viable long-term biotech investment for those who accept the inherent biotech risks. Read the full article on Seeking Alpha
Seeking Alpha • May 30

Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

Summary Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024. The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032. Data update from phase 1/2 NATHALI-01 study, using UCART20x22 for the treatment of patients with B-cell non-Hodgkin lymphoma, expected by the end of 2024. The global non-Hodgkin lymphoma market is expected to reach $11 billion by 2029. Read the full article on Seeking Alpha
Seeking Alpha • Aug 01

FDA clears Cellectis' investigational new drug application for lymphoma treatment

French clinical-stage biotech Cellectis (NASDAQ:CLLS) on Monday said the U.S. Food and Drug Administration (FDA) had cleared its investigational new drug (IND) application for its CAR-T treatment UCART20x22 for non-Hodgkin lymphoma. The company can now start a phase 1/2a clinical trial in patients with relapsed or refractory non-Hodgkin lymphoma. CLLS said it plans to begin enrolling patients in the study in H2 this year. U.S.-listed shares of CLLS were 2.7% higher at $3.08 after hours.
Seeking Alpha • Jul 13

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential

Phase I trials mean more usual for Cellectis. Cellectis is pursuing low-hanging fruit indications. New pipeline programs and their IP position offer upside on top of their CAR-T programs.
Seeking Alpha • Jun 22

Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside

Cellectis S.A. is an early clinical-stage immuno-oncology biotechnology company specializing in gene-edited T-cells that express chimeric antigen receptors for treating cancer. Cellectis offers a specialization in gene-editing enabling their CAR-T product candidates to have additional safety and efficacy attributes alongside healthy tissue-protective measures enabling high tolerance oncology therapeutics. Cellectis' pipeline has 7-internal candidates and 5-external candidates with internal clinical-stage indications covering acute lymphoblastic leukemia (UCART22: Phase 1), acute myeloid leukemia (UCART123: Phase 1), and multiple myeloma (UCARTCS1: Phase 1). Cellectis is not in the greatest financial position with cash of $211M (March 2021) pulled down by -$169M in TTM cash burn equating to about 1.25 years of operational funding, but in April 2021 Cellectis ran their +$45.5M ATM offering while the company states it should fund operations into early 2023. In summary, the author projects Cellectis S.A. as a "buy" at a 3-4 year price target of $70 (+382% upside).

Shareholder Returns

CLLSUS BiotechsUS Market
7D1.0%1.1%0.8%
1Y132.3%27.5%24.2%

Return vs Industry: CLLS exceeded the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: CLLS exceeded the US Market which returned 21.5% over the past year.

Price Volatility

Is CLLS's price volatile compared to industry and market?
CLLS volatility
CLLS Average Weekly Movement9.5%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: CLLS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CLLS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999227Andre Choulikawww.cellectis.com

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).

Cellectis S.A. Fundamentals Summary

How do Cellectis's earnings and revenue compare to its market cap?
CLLS fundamental statistics
Market capUS$232.18m
Earnings (TTM)-US$67.23m
Revenue (TTM)US$75.11m
3.1x
P/S Ratio
-3.5x
P/E Ratio

Is CLLS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLLS income statement (TTM)
RevenueUS$75.11m
Cost of RevenueUS$0
Gross ProfitUS$75.11m
Other ExpensesUS$142.34m
Earnings-US$67.23m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.93
Gross Margin100.00%
Net Profit Margin-89.51%
Debt/Equity Ratio83.7%

How did CLLS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 14:42
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cellectis S.A. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Madhu KumarBaird
Lukas ShumwayBarclays